ArticleBMC psychiatry2026
Untargeted metabolomics reveals plasma metabolic dysregulation in schizophrenia.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo screen significantly differential metabolites between schizophrenia (SZ) patients and healthy controls using univariate analysis combined with orthogonal partial least squares discriminant analysis (OPLS-DA), and to provide experimental evidence for disease-related research.
methodsPlasma samples were collected from 30 SZ patients and 30 healthy controls for untargeted metabolomics analysis. T-test together with OPLS-DA was applied to screen differential metabolites, and pathway enrichment analysis was performed to identify the core metabolic pathways involved.
resultsA total of 1,129 metabolites were identified by untargeted metabolomics. Using the thresholds of t-test P < 0.05 and VIP > 1.0(with false discovery rate < 0.05), 237 significantly differential metabolites were screened out. Three-level chemical taxonomy annotation showed that differential metabolites were mainly enriched in lipids and lipid-like molecules, organic acids and derivatives, and organoheterocyclic compounds (collectively accounting for nearly 70%), with amino acids, peptides and analogues being the core subclass. MetPA and MSEA pathway enrichment analyses revealed that differential metabolites were predominantly enriched in amino acid metabolism (biosynthesis of amino acids, alanine, aspartate and glutamate metabolism, glycine, serine and threonine metabolism), energy metabolism (glycolysis and TCA cycle), and neurotransmitter-related pathways (GABAergic synapse).
conclusionDifferential metabolites in the plasma of SZ patients are mainly concentrated in amino acid metabolism, energy metabolism, and neurotransmitter-related pathways. These findings suggest that SZ is associated with altered plasma metabolites, particularly in amino acid, energy, lipid, and neurotransmitter-related metabolic pathways. Further studies with larger cohorts and independent validation are needed before these metabolites can be considered candidate biomarkers.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.